Cited by 157Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 100 of the 103 references it cites were found in a registry or an index; none of the 95 sources its claims cite is checked for support yet.

ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease

Open access
Lane-Donovan, Courtney, Herz, Joachim·2017·Trends in Endocrinology & Metabolism

Abstract

As the population ages, neurodegenerative diseases such as Alzheimer's disease (AD) are becoming a significant burden on patients, their families, and health-care systems. Neurodegenerative processes may start up to 15 years before outward signs and symptoms of AD, as evidenced by data from AD patients and mouse models. A major genetic risk factor for late-onset AD is the ɛ4 isoform of apolipoprotein E (ApoE4), which is present in almost 20% of the population. In this review we discuss the contribution of ApoE receptor signaling to the function of each component of the tripartite synapse - the axon terminal, the postsynaptic dendritic spine, and the astrocyte - and examine how these systems fail in the context of ApoE4 and AD.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review argues that ApoE receptors (the LDL receptor family) act as central regulators of synaptic function across all three compartments of the tripartite synapse, and that the ApoE4 isoform disrupts these neuromodulatory roles early in Alzheimer's disease. It proposes that ApoE4 drives neuronal dysfunction both by impairing amyloid-beta turnover and by blunting Reelin/ApoE receptor protection of the synapse.

Key findings

  • ApoE4 is a major late-onset AD risk factor: one copy roughly triples risk, two copies confer about a 90% lifetime risk, and allele frequency is 15–20%; ApoE2 appears protective and ApoE3 risk-neutral.
  • Reelin signaling through Apoer2/Lrp8 and Vldlr phosphorylates Dab1, which boosts NMDAR-mediated calcium influx and LTP while inhibiting GSK3β and tau phosphorylation; Reelin application to hippocampal slices prevents Aβ-induced LTP reduction, and intraventricular Reelin improves learning and memory in mice.
  • Aβ oligomers oppose Reelin via calcineurin/STEP-driven NMDAR internalization and via caspase-3/Akt-mediated GSK3β activation, reducing LTP; Reelin-deficient mice overexpressing Aβ are heavily impaired on the Morris Water Maze.
  • ApoE4's structural instability (molten globule tendency, aggregation at 37°C) stalls endosomal recycling of ApoE receptors and co-trapped glutamate receptors, producing a state of "Reelin resistance"; ApoE4 targeted-replacement mice and human ApoE4 carriers show reduced dendritic spine complexity.
  • Presynaptically, Reelin acting through Apoer2/Vldlr raises intracellular calcium and selectively enhances fusion of VAMP7-containing vesicles; ApoE4 TR mice show decreased glutamate, increased glutamine, and late increases in vglut1.
  • Astrocytic Lrp4 mediates agrin-driven ATP release, which is converted to adenosine and suppresses presynaptic glutamate release via A1 receptors; ApoE4 limits astrocytic synaptic pruning and causes the greatest glial activation.

Methods

  • Narrative review; no primary data collection or new experiments.
  • Synthesizes published human, mouse, and in vitro literature on ApoE, LDL receptor family members, Reelin, and AD pathology.
  • Organizes evidence by tripartite synapse compartment (postsynaptic spine, axon terminal, astrocyte) and by signaling pathway (Reelin/Dab1, calcium homeostasis, actin polymerization, endocytic trafficking).

Limitations

  • Stated: the authors list unresolved questions, including whether ApoE4 represents gain or loss of function, whether ApoE isoforms affect presynaptic VAMP7-vesicle mobilization, the mechanism by which ApoE influences astrocytic pruning, how Lrp4 increases astrocytic ATP release, and which molecular targets could ameliorate ApoE4's endocytic recycling effects.
  • Stated: definitive human evidence that Reelin is protective is largely lacking; the role of Lrp1 in ApoE-isoform effects on pruning "remains to be demonstrated"; the impact of altered presynaptic glutamate production in vivo requires follow-up.
  • Evident from the text: as a review it presents no new data, and several mechanistic claims rest on mouse models or slice preparations whose translation to human AD is not established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.tem.2016.12.001

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 95 cited sources checked · 0 supported · 0 flagged

Show all 61 claims

  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 7
31 of 31
  • The paper relies on this without support.

    Mechanisms of ApoE/ApoE receptor signaling and ApoE4 effects observed in mouse models and cell studies are relevant to human Alzheimer's disease.

    “ApoE4 targeted replacement mice have a reduction in dendritic spine complexity, a finding that is mirrored in human ApoE4 carriers [67].”
  • The paper relies on this without support.

    The tripartite synapse framework captures the relevant sites of ApoE/ApoE receptor action in Alzheimer's disease.

    “We divide our discussion based on the three components of the tripartite synapse – the post-synaptic spine, the axon terminal, and the astrocyte – and delineate the newly discovered roles of ApoE receptor signaling at each of these compartments (Figure 1).”
  • The paper relies on this without support.

    Mechanisms of ApoE and Lrp4 function observed in mouse models apply to human Alzheimer's disease.

    “ApoE4 promotes neuronal dysfunction at the earliest stages of the pathology, leading up to the clinical manifestation of AD”
3 of 3

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 103 references

3 of the 103 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 101–101 of 101

Metadata

Authors
Lane-Donovan, C., & Herz, J.
Affiliations
University of Freiburg (DE)
Corresponding author
Herz, Joachim
Venue
Trends in Endocrinology & Metabolism
Publisher
Elsevier BV
Published
2017-04
Volume
28
Issue
4
Pages
273-284
ISSN
1043-2760 (ISSN-L)
OpenAlex
W2568317134
Cited by
157
References
103
Citations by year
2026: 13 · 2025: 20 · 2024: 17 · 2023: 18 · 2022: 18 · 2021: 25 · 2020: 13 · 2019: 14 · 2018: 12 · 2017: 7
FWCI
1.54
Type
journal article
Language
en
Open access
Locations
  • Trends in Endocrinology and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (RF1AG053391, F30AG047799)
  • National Heart, Lung, and Blood Institute (R37HL063762)
  • National Institute of Neurological Disorders and Stroke (R01NS093382)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, apolipoprotein E, APOE ε4, apoE receptors, tripartite synapse, synapses, axon terminals, dendritic spines, astrocytes, neurodegeneration, late-onset Alzheimer's disease, genetic risk factors
MeSH terms
Reelin Protein, Alzheimer Disease, Animals, Apolipoproteins E, Disease Models, Animal, Female, Humans, Male, Synapses, Low Density Lipoprotein Receptor-Related Protein-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review